Beam Therapeutics BEAM Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's change in accrued liabilities?
- Beam Therapeutics (BEAM) reported change in accrued liabilities of -$16.26M in Q1 2026.
- How has Beam Therapeutics's change in accrued liabilities changed year-over-year?
- Beam Therapeutics's change in accrued liabilities increased by 11.9% year-over-year, from -$18.46M to -$16.26M.
- What is the long-term trend for Beam Therapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2024), Beam Therapeutics's change in accrued liabilities has grown at a 14.6% compound annual growth rate (CAGR), from $43.91M to -$57.69M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.